OUR PIPELINE
MS
ONCOLOGY
| REGIMEN | DIsease | Preclinical | Phase 1 | Phase 2 | Phase 3 | Registration Status | Learn More | |
|---|---|---|---|---|---|---|---|---|
|
Single Agent |
Ublituximab monotherapy anti-CD20 mAb | Relapsing MS |
ULTIMATE I and II
|
 |
||||
| Umbralisib monotherapy P13k-delta & CK1 -epsilon inhibitor | R/R MZL |
UNITY-NHL
|
PDUFA: 2/15/2021 | |
||||
| Umbralisib monotherapy | R/R FL |
UNITY-NHL
|
PDUFA: 6/15/2021 | |
||||
|
Combination |
Umbralisib + ublituximab (U2) | R/R NHL |
UNITY-NHL
|
|
||||
| Umbralisib + ublituximab (U2) | Frontline and R/R CLL |
UNITY-CLL
|
|
|||||
| Ublituximab + ibrutinib | R/R high-risk CLL |
GENUINE
|
|
|||||
| Umbralisib + ublituximab + venetoclax | Frontline and R/R CLL |
ULTRA-V
|
|
|||||
| Umbralisib + ublituximab + TG-1701 (BTKi) | Frontline and R/R CLL & NHL | |
||||||
|
Early Pipeline |
Cosibelimab (TG-1501): anti-PD-L1 mAb | B-cell malignancies | |
|||||
| TG-1701: BTK inhibitor | B-cell malignancies | |
||||||
| TG-1801: anti-CD47/CD19 bispecific mAb | B-cell malignancies | |
||||||
| TG-1601: BET inhibitor | B-cell malignancies | |
||||||
|
ENROLLMENT COMPLETED
ENROLLMENT ONGOING
|
||||||||
|
ENROLLMENT COMPLETED
ENROLLMENT ONGOING
|
|||||
|---|---|---|---|---|---|
|
Single Agent |
|||||
| REGIMEN | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
|
MS |
Ublituximab monotherapy: anti-CD20 mAb
DiseaseRelapsing MS Learn More |
ULTIMATE I and II
|
|||
|
ONCOLOGY
|
Umbralisib monotherapy: P13k-delta & CK1 -epsilon inhibitor
DiseaseR/R MZL Learn More |
UNITY-NHL
PDUFA: 2/15/2021 |
|||
|
Umbralisib + Ublituximab (U2)
DiseaseR/R FL Learn More |
UNITY-NHL
PDUFA: 6/15/2021 |
||||
|
COMBINATION |
|||||
|---|---|---|---|---|---|
| REGIMEN | Preclinical | Phase 1 | Phase 2 | Phase 3 | |
|
ONCOLOGY
|
Umbralisib + ublituximab (U2)
DiseaseR/R NHL Learn More |
UNITY-NHL
|
|||
|
Umbralisib + ublituximab (U2)
DiseaseFrontline and R/R CLL Learn More |
UNITY-CLL
|
||||
|
Ublituximab + ibrutinib
DiseaseR/R high-risk CLL Learn More |
GENUINE
|
||||
|
Umbralisib + ublituximab + venetoclax
DiseaseFrontline and R/R CLL Learn More |
ULTRA-V
|
||||
|
Umbralisib + ublituximab + TG-1701 (BTKi)
DiseaseFrontline and R/R CLL & NHL Learn More |
|
||||
|
EARLY PIPELINE |
||||||
|---|---|---|---|---|---|---|
| REGIMEN | Preclinical | Phase 1 | Phase 2 | Phase 3 | ||
|
ONCOLOGY
|
Cosibelimab (TG-1501): anti-PD-L1 mAb
DiseaseB-cell malignancies Learn More |
|||||
|
TG-1701: BTK inhibitor
DiseaseB-cell malignancies Learn More |
||||||
|
TG-1801: anti-CD47/CD19 bispecific mAb
DiseaseB-cell malignancies Learn More |
||||||
|
TG-1601: BET inhibitor
DiseaseB-cell malignancies Learn More |
||||||
|
The safety and efficacy of our investigational compounds have not been established. These products have not been approved by the US Food and Drug Administration or other regulatory authorities. |
||||||